New chemo cocktail aims to tackle rare brain tumors

NCT ID NCT07188441

Recruiting now Disease control Sponsor: Chengcheng Guo Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two chemotherapy drugs, teniposide and cisplatin, in 40 people newly diagnosed with central malignant germ cell tumors. The goal is to see if the combo is safe and effective at shrinking tumors and prolonging survival. Researchers will also look for biomarkers that might predict who benefits most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teniposide and cisplatin
What this could lead to: If successful, this combination could offer a new treatment option to control central malignant germ cell tumors and extend survival.
What could go wrong: This is a small, early-phase trial with only 40 participants and no comparison group, so results may not be definitive. Side effects from chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL MALIGNANT GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system germ cell tumor germ cell tumor granular cell tumor Neoplasms, Germ Cell and Embryonal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL MALIGNANT GERM CELL TUMOR GCT GERM CELL TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.